Obtaining the data and biomarkers to drive decisions
Estimates vary, but the time and cost of bringing a drug successfully to market is over 12 years and greater than one billion dollars. These staggering figures are driven by a >95% failure rate.
Most assessments of these high failure rates contend that, although the ultimate failure occurs in the clinic, that "clinical" failure is a more holistic problem that starts at discovery and extends all the way to the clinic.
This free eBook focuses on using metabolomics throughout the R&D process as an ally improve the clinical success rate. By producing a comprehensive and meaningful assessment of the molecular phenotype one can enrich the biomarker and information armament to inform decisions across the continuum.